Who are Syntommetrine and Carbetocin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxytocin 5 Usp Units In Dextrose 5%, Oxytocin (Low dose), Syntocinon (Oxytocin), Placebo then intranasal oxytocin, Argipressin, oxytocin nasal spray.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/syntommetrine-and-carbetocin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Syntommetrine and Carbetocin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Syntommetrine and Carbetocin (Syntommetrine and Carbetocin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Uterotonic agent. Area: Obstetrics.

marketed Uterotonic agent Oxytocin receptor Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Syntommetrine and Carbetocin (Syntommetrine and Carbetocin) — National University Hospital, Singapore. Syntommetrine (ergot alkaloid + oxytocin combination) and Carbetocin (oxytocin analogue) stimulate uterine muscle contraction to prevent or treat postpartum hemorrhage.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Syntommetrine and Carbetocin TARGET	Syntommetrine and Carbetocin	National University Hospital, Singapore	marketed	Uterotonic agent	Oxytocin receptor
Oxytocin 5 Usp Units In Dextrose 5%	OXYTOCIN	Fresenius Kabi	marketed	Adrenocorticotropic Hormone [EPC]	Oxytocin receptor	1980-01-01
Oxytocin (Low dose)	Oxytocin (Low dose)	The University of Texas Medical Branch, Galveston	marketed	Neuropeptide agonist	Oxytocin receptor (OXTR)
Syntocinon (Oxytocin)	Syntocinon (Oxytocin)	KU Leuven	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
Placebo then intranasal oxytocin	Placebo then intranasal oxytocin	MacDonald, Kai, M.D.	marketed	Neuropeptide	Oxytocin receptor (OXTR)
Argipressin	Argipressin	Kristina Svennerholm	marketed		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
oxytocin nasal spray	oxytocin nasal spray	University of Electronic Science and Technology of China	marketed	Neuropeptide	Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Uterotonic agent class)

Hadassah Medical Organization · 1 drug in this class
National University Hospital, Singapore · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Syntommetrine and Carbetocin — Competitive Intelligence Brief. https://druglandscape.com/ci/syntommetrine-and-carbetocin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab